)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ALK-Abelló
ALK-Abelló (ALK) investor relations material
ALK-Abelló Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary24 Aug, 2026
Executive summary
Achieved 18% year-over-year revenue growth in Q2 2026, driven by strong tablet and anaphylaxis product sales and reduced risks, with double-digit increases across all regions.
EBIT increased 19% year-over-year in Q2, supported by sales growth and improved gross margin, partially offset by higher R&D and commercial investments.
EBIT margin for H1 reached 28%, reflecting operational leverage and efficiency.
Updated full-year revenue outlook to 14–16% growth in local currencies, with EBIT margin expected around 26%.
Strategic execution advanced with successful paediatric tablet roll-out and progress in new product development.
Financial highlights
Revenue for H1 2026 reached DKK 3,566 million, up 18% from H1 2025; Q2 revenue was DKK 1,795 million, up 18% year-over-year.
Gross profit increased to DKK 2,423 million, with gross margin improving to 68% from 66% year-over-year.
Operating profit (EBIT) rose to DKK 1,015 million, a 20% increase year-over-year, maintaining a 28% EBIT margin.
Net profit for H1 was DKK 776 million (+26% YoY); EPS H1: DKK 3.5 (diluted).
Free cash flow improved to DKK 889 million, up from DKK 546 million in H1 2025; equity ratio at 71%.
Outlook and guidance
Revenue growth for 2026 now expected at 14–16% in local currencies, up from previous 13–16%, driven by volume increases in tablets and anaphylaxis products.
EBIT margin forecasted at approximately 26%; gross margin anticipated to be slightly higher than last year.
R&D costs to be slightly above 10% of revenue; S&M expenses to rise to support market shaping.
CAPEX projected at DKK 400 million; free cash flow expected to slightly exceed DKK 1,000 million.
Shipment timing in Japan/China may cause fluctuations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ALK-Abelló
- No ordinary dividend; Alan Main joined the Board as governance measures were approved.ALK
AGM 2022 - Governance proposals passed; directors were re-elected and no ordinary dividend was declared.ALKAGM 2024
- 2022 accounts approved, Board refreshed, and no ordinary dividend declared.ALKAGM 2023
- 15% revenue growth and 65% EBIT increase, with strong outlook and major product launches ahead.ALKQ4 2024
- Q2 2026 saw 18% revenue and 19% EBIT growth, with upgraded full-year outlook.ALKQ2 2026
- 2025 growth, a DKK 355 million dividend and approved governance changes.ALKAGM 2026
- Record growth, reinvestment, Board re-election and no 2024 dividend.ALKAGM 2025
- Q3 revenue up 18% and EBIT margin at 23%, driven by tablet and JextⓇ sales, with neffyⓇ deal fueling growth.ALKQ3 2024
- Q1 saw 12% revenue growth, 50% EBIT surge, and strong pediatric and neffy® product momentum.ALKQ1 2025
Next ALK-Abelló earnings date
Q3 202618 Nov, 2026
ALK-Abelló
Next ALK-Abelló earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company produces test kits for allergy and asthma assessment; allergy alert systems; blood pressure monitors; clinical chemistry analyzers; immunoassays and biochemistry instruments, Bruker X-ray fluorescence spectrometers, and various other products. It also provides allergy diagnostic solutions, including skin testing systems; test kits to identify urushiols that cause natural rubber allergies; laboratory equipment to measure patient serum samples suspected of having restricted proteins; a compact EDM device that helps dermatologists treat contact dermatitis via electromagnetic healing vibrations; a patch test panel to help prevent hospital patients from developing hypersensitivity and subsequent allergies during their stay; a test kit for the identification of contact urticaria triggered by nickel based alloys used in jewellery making and dental implants.